{"classes":[{"categories":[{"measurements":[{"comment":"Not enough events occurred to calculate upper limit","groupId":"OG000","lowerLimit":"1.9","upperLimit":"NA","value":"7.6"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"15.0","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG000","title":"Arm A (Continuation Phase)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm C (Continuation Phase)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"5 years","title":"Progression-free Survival of Patients Treated With Combination Therapy","type":"SECONDARY","unitOfMeasure":"Months"}